Evaluating decision aids for patients with renal cell carcinoma

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to assess the impact of two decision aids designed for patients with renal cell carcinoma (RCC) on their decision-making process and the quality of their treatment choices. The decision aids will provide detailed information about treatment options, including potential benefits and side effects, to help patients make informed decisions aligned with their values. The study focuses on patients with either local or metastatic RCC who are facing treatment decisions. By implementing these aids, the study seeks to enhance patient knowledge, reduce anxiety, and improve overall health outcomes.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients clinically diagnosed with RCC
* Patients facing a decision which is addressed in the decision aids (T1 tumor or metastatic disease)
* Written informed consent

Exclusion Criteria:

* Patients who are not able to fill in a questionnaire or undergo an interview individually

Where it's running

• St. Antonius Ziekenhuis
  Nieuwegein, Utrecht, Netherlands Recruiting

Study contacts

• Study coordinator: Cato Bresser
• Email: c.bresser@antoniusziekenhuis.nl
• Phone: 0631143301

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• High-dose radiotherapy for renal cell carcinoma treatment

  This study is testing whether a higher dose of radiation therapy can be a better option for people with kidney cancer compared to the standard treatment.

  Recruiting Royal Marsden NHS Foundation Trust · London · NCT06995664

• Plasma DNA Methylation to Classify Kidney Masses Before Surgery

  This study tests a blood-based DNA methylation test to help distinguish malignant kidney cancers from benign kidney masses in adults who are planned for kidney surgery.

  Recruiting RenJi Hospital · Shanghai, Shanghai Municipality · NCT07874542

• Your Kidney Cancer Immunotherapy: How You Get It and If Labs Can Be At Home

  This study tests whether people with kidney cancer prefer intravenous or subcutaneous immunotherapy and whether at‑home lab draws plus telehealth visits before treatment are practical.

  Recruiting at 7 sites Phase 4 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT07872553

• Intensified monitoring to personalize cabozantinib dosing in advanced kidney cancer

  We will test whether closer pharmacology-based monitoring helps people with advanced kidney cancer tolerate cabozantinib better while keeping its effect against the cancer.

  Recruiting Centro di Riferimento Oncologico - Aviano · Aviano, Pordenone · NCT07805122

• Who’s at high risk after RCC surgery? Real-world clues from French registry

  This study looks at real-world data from French RCC patients who had local or high-risk locally advanced disease to see how they do after surgery and how doctors decide on adjuvant treatment.

  Recruiting University Hospital, Bordeaux · Bordeaux · NCT07753343

• First-in-human test of HH160 in people with advanced solid tumors

  HH160 is being tested to see if it is safe and how it behaves in the body, to see if it has early signs of helping various advanced cancers in adults.

  Recruiting at 3 sites Phase 1 Huahui Health · Waratah, New South Wales and 2 other locations · NCT07623369

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.